🛒 Starr v. VSL Pharmaceuticals VSL#3 Probiotic $20M Settlement

The defendants allegedly falsely advertised and misrepresented VSL#3 probiotic products, including claims about the product's composition and benefits, and allegedly sold a reformulated product that did not match what consumers believed they were buying.

Individuals who purchased VSL#3 probiotic products between June 1, 2016 and June 19, 2019.

Pro rata share of a $20,000,000 settlement fund; reported at up to $20 per unit purchased, with a higher cap for class members who can document their purchases

2026-10-20

A class action settlement has been reached with VSL Pharmaceuticals, Inc., Leadiant Biosciences, Inc. and Alfasigma USA, Inc. (the Starr matter) over allegations that VSL#3 probiotic products were falsely advertised to consumers. The defendants deny wrongdoing and the Court has not decided who is right. The official settlement website lists the class period as purchases between June 1, 2016 and June 19, 2019. Claim Forms must be submitted online or postmarked no later than October 20, 2026; the same date is the deadline to exclude yourself or object to the settlement, and the Final Approval Hearing is scheduled for January 6, 2027.